Q-omics provides the consensus-scored CD93 profile across patient tissues and cancer cell-line models. CD93 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CD93 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, CD93 RNA expression shows 25,597 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where CD93 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD93 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD93 survival associations across molecular data types. CD93 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD93 RNA expression–survival associations across cancer types. High CD93 expression shows unfavorable associations in KIRP, UVM, LGG and STAD, but favorable associations in KIRC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CD93 RNA expression.
This table summarizes CD93 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD93. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD93 shows lower tumor expression in LUAD, KICH and LUSC and higher tumor expression in KIRC, HNSC and LIHC. The LUAD box plot shows higher CD93 RNA expression in normal versus tumor tissue (log2 FC = −2.302, t-test p < 0.001).
This table shows molecular features associated with CD93 in patient tissues and cancer cell lines. In patient samples, CD93 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD93 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
